FGF21 and diabetes mellitus: When categorizing the MD patients according to their clinical phenotypes (Figure 4D), we observed that FGF-21 levels were preferentially increased in patients with myopathy, exercise intolerance, and CPEO, and also discriminated patients with diabetes mellitus and hearing loss.